Pricey Inclisiran Is Rolling Out: a 'Buy-and-Bill' Model May Smooth Its Path
At $6,500 per year, without outcomes data, inclirisan faces hurdles. Doctors still expect it to be “transformative.”
Source: tctmd.com
📰 Daniel Soffer News
Page 2 - Daniel Soffer News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Daniel Soffer. Real-time updates on events, politics, business and more.